<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2476">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128929</url>
  </required_header>
  <id_info>
    <org_study_id>H01</org_study_id>
    <nct_id>NCT05128929</nct_id>
  </id_info>
  <brief_title>Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).</brief_title>
  <acronym>SATURN</acronym>
  <official_title>Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, double-blind, study of H01 (Hymecromone) in adults&#xD;
      with pulmonary hypertension (PH). The primary objective of this study is to evaluate the&#xD;
      safety and tolerability of oral H01 and the potential benefit of oral H01 on clinical&#xD;
      measures of PH disease severity over 24 weeks.&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
      Oral H01, at doses of 1600 mg per day, will be a safe and well-tolerated agent in adults with&#xD;
      pulmonary hypertension over 24 weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study's objectives are to evaluate:&#xD;
&#xD;
        -  The changes in clinical and functional measures (pulmonary function test, pulmonary&#xD;
           vascular resistance, mean pulmonary arterial pressure, and 6 Minute Walk Distance Test)&#xD;
           in adults with PH treated with oral H01&#xD;
&#xD;
        -  The safety and tolerability of the use of oral H01 for PH over 24 weeks using health&#xD;
           criteria/evaluations (Common Terminology Criteria for Adverse Events (CTCAE), quality of&#xD;
           life (QOL) score, EMPHASIS-19 score and St George Respiratory Questionnaire (SGRQ)&#xD;
           score)&#xD;
&#xD;
        -  To investigate the clinical efficacy, pharmacokinetic (PK) and pharmacodynamic (PD)&#xD;
           markers (serum HA concentration, inflammatory markers and cytokines, NT-proBNP, and H01&#xD;
           and metabolite serum concentrations) in this population following oral H01 use&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulmonary Vascular Resistance (PVR)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in pulmonary vascular resistance (PVR) measured by right heart catheterization (RHC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Safety and Tolerability of H01</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>The safety and tolerability of H01 in adults with pulmonary hypertension using the Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Pulmonary Arterial Pressure (mPAP)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in mean pulmonary arterial pressure (mPAP) by RHC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Distance Test (6 MWDT)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in 6 minute walk distance as measured by 6 MWDT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) score, EMPHASIS-19 score and St George Respiratory Questionnaire (SGRQ) score</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in quality of life (QOL) score, EMPHASIS-19 score and St George Respiratory Questionnaire (SGRQ) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HA concentration</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in serum HA concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in NT-proBNP</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory markers and PH-specific biomarkers (ESR, CRP, D-dimer, WCC, ferritin, LDH, NLRC3)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in inflammatory markers and PH-specific biomarkers (ESR, CRP, D-dimer, WCC, ferritin, LDH, NLRC3)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pro-inflammatory cytokines (IL-1, IL-6, IFN-α and IFN-γ)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in pro-inflammatory cytokines (IL-1, IL-6, IFN-α and IFN-γ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Expiratory Volume in one second (FEV1)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in Forced Expiratory Volume in one second (FEV1)</description>
  </other_outcome>
  <other_outcome>
    <measure>Forced Vital Capacity (FVC) from Pulmonary Function Test (PFT)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in Forced Vital Capacity (FVC) from pulmonary function test (PFT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Lung Capacity (TLC) from Pulmonary Function Test (PFT)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in Total Lung Capacity (TLC) from pulmonary function test (PFT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Lung diffusion capacity (DLCO) from Pulmonary Function Test (PFT)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in Lung diffusion capacity (DLCO) from pulmonary function test (PFT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exhaled breath condensate (EBC) hyaluronan concentrations</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Change in exhaled breath condensate (EBC) hyaluronan concentrations</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics (H01 and metabolite serum concentrations)</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Describe the pharmacokinetics (H01 and metabolite serum concentrations)</description>
  </other_outcome>
  <other_outcome>
    <measure>HA fragment size</measure>
    <time_frame>Baseline to end of treatment (Week 24)</time_frame>
    <description>Describe HA fragment size</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment Oral Hymecromone (H01)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be initiated. Participants will be administered 800 mg of oral H01 two times a day (total dose: 1600 mg/day). Participants will continue to be on treatment for 24 weeks and will be monitored with assessments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to placebo will receive oral tablet placebo (inactive ingredients) four times a day. Participants will continue to be on placebo for 24 weeks and will be monitored with assessments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hymecromone (H01)</intervention_name>
    <description>800 mg oral H01 two times a day (total dose: 1600 mg/day).</description>
    <arm_group_label>Experimental Treatment Oral Hymecromone (H01)</arm_group_label>
    <other_name>Cantabiline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet placebo (inactive ingredients) four times a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Classified as WHO functional class II/III/IV despite treatment with maximally&#xD;
             tolerated doses of 2 or more treatment modalities (exp. PDE5 inhibitors, guanylate&#xD;
             cyclase stimulators, endothelin receptor antagonists, and prostanoids)&#xD;
&#xD;
          2. Baseline 6MWT: greater than 100 meters and less than 550 meters&#xD;
&#xD;
          3. Established diagnosis of Group 3 pulmonary hypertension as a result of interstitial&#xD;
             lung disease OR established diagnosis of Group 1 pulmonary hypertension as a result of&#xD;
             connective tissue disease, idiopathic, hereditary, drugs, or toxins.&#xD;
&#xD;
          4. Right heart catheterization at randomization showing pre-capillary pulmonary&#xD;
             hypertension (mPAP ≥ 25 mmHg and PVR &gt; 400 dynes * sec * cm^ -5) and:&#xD;
&#xD;
               -  PCWP &lt;20 mmHg for Group 3 PH patients and a PCWP &lt;15 for Group 1 PAH patients&#xD;
&#xD;
          5. Participants on chronic medication for PAH, PH, or underlying lung disease must be on&#xD;
             a stable and optimized dose for at least 90 days prior to the first dose of the study&#xD;
             drug.&#xD;
&#xD;
          6. Female participants who are heterosexually active must use an acceptable method of&#xD;
             contraception: condoms (male or female) with or without a spermicidal agent, diaphragm&#xD;
             or cervical cap with spermicide, IUD, or Hormone-based contraceptive&#xD;
&#xD;
          7. Be able to provide written informed consent and comply with study requirements&#xD;
&#xD;
          8. Be able to read, speak and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with a diagnosis of PAH or PH for reasons due to any of the following:&#xD;
&#xD;
               -  Group 2, 4, or 5&#xD;
&#xD;
               -  Group 1 due to HIV, veno-occlusive disease, porto-pulmonary hypertension,&#xD;
                  congenital heart disease&#xD;
&#xD;
               -  Group 3 due to severe chronic obstructive pulmonary disease (COPD) or obstructive&#xD;
                  sleep apnea (OSA)&#xD;
&#xD;
                    -  Note: participants with overlapping syndromes will be evaluated on a&#xD;
                       case-by-case basis by the recruiting physician*&#xD;
&#xD;
          2. Total Lung Capacity (TLC) less than 60% predicted&#xD;
&#xD;
          3. FEV1/FVC less than 50% predicted or FEV1 less than 55% predicted&#xD;
&#xD;
          4. Inability to safely attempt completion of the 6MWD test&#xD;
&#xD;
          5. Use of experimental PAH treatments within the past 3 months&#xD;
&#xD;
          6. Current systemic treatment with hymecromone&#xD;
&#xD;
          7. Left sided heart disease as defined by either a PCWP greater than 20 mmHg and/or left&#xD;
             ventricular ejection fraction less than 40%&#xD;
&#xD;
               -  Note: participants with abnormal left ventricular function attributable entirely&#xD;
                  to impaired left ventricular filling due to the effects of right ventricular&#xD;
                  overload (ie right ventricular hypertrophy and/or dilatation) are not excluded&#xD;
&#xD;
          8. Participants must not have 3 or more of the following left ventricular disease /&#xD;
             dysfunction risk factors:&#xD;
&#xD;
               -  Body mass index (BMI) greater than 30kg/m2&#xD;
&#xD;
               -  History of essential hypertension requiring medication&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
          9. Historical evidence of significant coronary disease established by any of the&#xD;
             following:&#xD;
&#xD;
               -  History of myocardial infarction&#xD;
&#xD;
               -  History of percutaneous coronary intervention or coronary artery bypass graft&#xD;
&#xD;
               -  Angiographic evidence of greater than 50% stenosis in at least one coronary&#xD;
                  artery&#xD;
&#xD;
               -  Positive stress test with imaging&#xD;
&#xD;
               -  Stable angina&#xD;
&#xD;
         10. Significant valvular heart disease as determined by more than moderate findings on&#xD;
             echocardiogram or history of valve replacement&#xD;
&#xD;
         11. Pregnant or actively breastfeeding&#xD;
&#xD;
         12. Female participants with childbearing potential not willing to use a form of birth&#xD;
             control (including abstinence) during the study&#xD;
&#xD;
         13. Inability to undergo right heart catheterization&#xD;
&#xD;
         14. Acute pulmonary embolism within 90 days of randomization&#xD;
&#xD;
         15. Exacerbation of underlying lung disease or active pulmonary or upper respiratory&#xD;
             infection within 30 days of randomizations&#xD;
&#xD;
         16. Use of any inhaled tobacco products or significant history of drug abuse within 3&#xD;
             months prior to randomization&#xD;
&#xD;
         17. Subject is receiving greater than 10L/min of oxygen supplementation by any mode of&#xD;
             delivery at rest at baseline&#xD;
&#xD;
         18. Body mass index greater than 40kg/m2&#xD;
&#xD;
         19. Participants with history of dysphagia, achalasia, or difficulty swallowing capsules,&#xD;
             tablets or pills&#xD;
&#xD;
         20. Participants with liver failure or AST or ALT greater than 2 times the upper limit of&#xD;
             normal&#xD;
&#xD;
         21. Participants with total bilirubin levels greater than 2 times the upper limit of&#xD;
             normal&#xD;
&#xD;
         22. Participants with CrCl less than 45&#xD;
&#xD;
         23. Use of any investigational drug/device, or participation in any investigational study&#xD;
             with therapeutic intent within 30 days prior to randomization&#xD;
&#xD;
         24. Known allergy to hymecromone or any component thereof&#xD;
&#xD;
         25. Known allergy to any component of placebo (including wheat allergy, celiac disease,&#xD;
             rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or&#xD;
             glucose-galactose malabsorption)&#xD;
&#xD;
         26. Physician concern that participant may not adhere to the study protocol&#xD;
&#xD;
         27. Significant psychiatric, addictive, or other disorder that compromises the subject's&#xD;
             ability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Roham T. Zamanian</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Six Minute Walk Distance Test (6 MWDT)</keyword>
  <keyword>Right Heart Catheterization (RHC)</keyword>
  <keyword>Pulmonary Vascular Resistance (PVR)</keyword>
  <keyword>Pulmonary Function Test (PFT)</keyword>
  <keyword>Mean Pulmonary Arterial Pressure (mPAP)</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Hyaluronan</keyword>
  <keyword>Hymecromone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

